Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(44 sites) United States
University of California Irvine Medical Center, Orange, California UCLA Dept of Medicine - Hematology/Oncology, Santa Monica, Santa Monica, California Northwestern University, Chicago, Illinois University of Kansas Cancer Center, Westwood, Kansas Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey NYU Langone Medical Center - NYU Medical Oncology Associates, New York, New York Columbia University, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York Duke Children's Hospital and Health Center, Durham, North Carolina Wake Forest University Baptist Health, Winston-Salem, North Carolina UT Southwestern Medical Center, Dallas, Texas Virginia Mason Medical Center, Seattle, Washington Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Henan Cancer Hospital, Zhengzhou, Henan Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang France
Site FR33005, Vaillant, Villejuif Site FR33001, Saint-Herblain Japan
Aichi Cancer Center, Nagoya, Aichi-ken National Cancer Center Hospital East, Kashiwa, Chiba Kanagawa Cancer Center, Yokohama, Kanagawa Kindai University Hospital, Sakai, Osaka The University of Osaka Hospital, Suita, Osaka National Cancer Center Hospital, Chuo-ku, Tokyo The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo Puerto Rico
PanOncology Trials, San Juan South Korea
Site KR82004, Seongnam-si, Gyeonggi-do Site KR82001, Guro-gu, Seoul Site KR82002, Jongno-gu, Seoul Site KR82003, Seocho-gu, Seoul Site KR82005, Seodaemun-gu, Seoul